| Literature DB >> 31130572 |
Koichi Arimura1, Koji Iihara1, Tetsu Satow2, Ataru Nishimura1, So Tokunaga3, Nobuyuki Sakai4.
Abstract
Japan has a rapidly aging population and the application of neuroendovascular therapy (NET) for cerebrovascular diseases among elderly patients has increased, but feasibility and safety of NET for elderly patients are still debated. Therefore, this study aimed to elucidate feasibility and safety of NET by analyzing the Japanese nationwide database, the Japanese Registry of Neuroendovascular Therapy 3 (JR-NET 3). In total, 35,972 patients in the JR-NET 3 were analyzed retrospectively. "Elderly patients" were defined as those aged ≥75 years. Approximately one-quarter of patients who received NET were elderly patients. The proportion of patients with modified Rankin Scale (mRS) 0-2 before treatment and 30 days after NET was significantly low across all diseases in the elderly patients. Technical success rates were generally high across all procedures, but complication rate was significantly higher among elderly patients; ischemic complications were significantly higher with NET for unruptured aneurysms (UA) and carotid artery stenosis (CAS). Multivariate analysis revealed that mRS 0-2 before treatment [odds ratio (OR): 0.56, 95% confidence interval (CI): 0.34-0.94, P = 0.03], middle cerebral artery aneurysm (OR: 0.33, 95% CI: 0.12-0.92, P = 0.04), and complete obliteration (OR: 0.66, 95% CI: 0.44-0.97, P = 0.03) were associated with ischemic complications with NET for UA. Moreover, mRS 0-2 before treatment (OR: 0.55, 95% CI: 0.36-0.86, P < 0.01), high intensity with time-of-flight magnetic resonance angiography (OR: 1.55, 95% CI: 1.03-2.32, P = 0.04), open-cell stent (OR: 2.20, 95% CI: 1.50-3.22, P <0.01) were associated with ischemic complications with NET for CAS. Taken together, our findings indicate that cautious and precise selection of patients suitable for NET is necessary.Entities:
Keywords: JR-NET 3; elderly; neuroendovascular therapy
Mesh:
Year: 2019 PMID: 31130572 PMCID: PMC6694018 DOI: 10.2176/nmc.oa.2018-0325
Source DB: PubMed Journal: Neurol Med Chir (Tokyo) ISSN: 0470-8105 Impact factor: 1.742
Characteristics of patients, treatments, and results of the procedure
| <75 y ( | ≥75 y ( | ||
|---|---|---|---|
| Age, mean ± SD | 59.5 ± 12.5 | 80.2 ± 4.3 | |
| Sex: Female, | 12,689 (48.8) | 4671 (47.0) | |
| Types of procedure, | |||
| All procedure ( | 26,025 (72.3) | 9947 (27.7) | |
| Ruptured AN ( | 4158 (70.9) | 1708 (29.1) | |
| Unruptured AN ( | 8788 (87.3) | 1282 (12.7) | |
| Acute ischemic stroke ( | 2085 (53.5) | 1812 (46.5) | |
| Carotid artery stenosis ( | 4682 (55.8) | 3706 (44.2) | |
| Intracranial artery stenosis ( | 666 (68.3) | 309 (31.7) | |
| Technical success rate, % | |||
| All procedures | 97.6 | 96.1 | <0.01 |
| Ruptured AN | 98.4 | 97.8 | 0.19 |
| Unruptured AN | 97.9 | 97.2 | 0.13 |
| Acute ischemic stroke | 89.1 | 86.1 | <0.01 |
| Carotid artery stenosis | 99.1 | 98.9 | 0.58 |
| Intracranial artery stenosis | 98.2 | 96.1 | 0.07 |
| Proportion of mRS 0–2 before and after treatment, % | |||
| All procedures | |||
| Before treatment | 88.7 | 79.0 | <0.01 |
| 30 days after treatment | 72.8 | 54.0 | <0.01 |
| Ruptured AN | |||
| Before treatment | 90.8 | 75.5 | <0.01 |
| 30 days after treatment | 57.1 | 22.4 | <0.01 |
| Unruptured AN | |||
| Before treatment | 96.2 | 89.3 | <0.01 |
| 30 days after treatment | 93.3 | 80.0 | <0.01 |
| Acute ischemic stroke | |||
| Before treatment | 88.2 | 74.4 | <0.01 |
| 30 days after treatment | 23.2 | 12.8 | <0.01 |
| Carotid artery stenosis | |||
| Before treatment | 87.9 | 84.1 | <0.01 |
| 30 days after treatment | 82.1 | 76.0 | <0.01 |
| Intracranial artery stenosis | |||
| Before treatment | 85.3 | 70.0 | <0.01 |
| 30 days after treatment | 79.0 | 56.6 | <0.01 |
Statistically significant. AN: aneurysm, mRS: modified Rankin Scale, y: years.
Periprocedural complications
| Age | |||
|---|---|---|---|
| <75 y | ≥75 y | ||
| All patients, | |||
| All complications | 2475 (9.5) | 1097 (11.0) | <0.01 |
| Hemorrhagic | 693 (2.7) | 322 (3.2) | <0.01 |
| Ischemic | 1277 (4.9) | 547 (5.5) | 0.02 |
| Puncture site | 211 (0.8) | 84 (0.8) | 0.74 |
| Cholesterol embolism | 9 (0.03) | 2 (0.02) | 0.74 |
| Other systemic | 49 (0.19) | 34 (0.34) | <0.01 |
| Ruptured AN, | |||
| All complications | 543 (13.1) | 218 (12.8) | 0.80 |
| Hemorrhagic | 181 (4.4) | 73 (4.3) | 0.94 |
| Ischemic | 341 (8.2) | 130 (7.6) | 0.14 |
| Puncture site | 11 (0.3) | 2 (0.1) | 0.37 |
| Cholesterol embolism | 0 | 0 | – |
| Other systemic | 2 (0.05) | 2 (0.12) | 0.59 |
| Unruptured AN, | |||
| All complications | 840 (9.6) | 190 (14.8) | <0.01 |
| Hemorrhagic | 176 (2.0) | 20 (1.6) | 0.33 |
| Ischemic | 470 (5.3) | 140 (10.9) | <0.01 |
| Puncture site | 117 (1.3) | 15 (1.2) | 0.79 |
| Cholesterol embolism | 0 | 0 | – |
| Other systemic | 6 (0.07) | 3 (0.23) | 0.10 |
| Acute ischemic stroke, | |||
| All complications | 281 (13.5) | 231 (12.7) | 0.51 |
| Hemorrhagic | 186 (8.9) | 169 (9.3) | 0.70 |
| Ischemic | 64 (3.1) | 30 (1.7) | <0.01 |
| Puncture site | 9 (0.4) | 13 (0.7) | 0.29 |
| Cholesterol embolism | 1 (0.05) | 0 (0) | 1 |
| Other systemic | 5 (0.24) | 10 (0.55) | 0.13 |
| Carotid artery stenosis, | |||
| All complications | 338 (7.2) | 333 (9.0) | <0.01 |
| Hemorrhagic | 40 (0.9) | 25 (0.7) | 0.38 |
| Ischemic | 178 (3.8) | 195 (5.3) | <0.01 |
| Puncture site | 52 (1.1) | 43 (1.2) | 0.84 |
| Cholesterol embolism | 7 (0.15) | 3 (0.08) | 0.53 |
| Other systemic | 24 (0.51) | 21 (0.57) | 0.76 |
| Intracranial artery stenosis, | |||
| All complications | 76 (11.4) | 33 (10.7) | 0.83 |
| Hemorrhagic | 20 (3.0) | 9 (2.9) | 1 |
| Ischemic | 37 (5.6) | 13 (4.2) | 0.44 |
| Puncture site | 5 (0.8) | 1 (0.3) | 0.67 |
| Cholesterol embolism | 0 | 0 | – |
| Other systemic | 1 (0.15) | 3 (0.97) | 0.10 |
Statistically significant. AN: aneurysm, y: years.
Risk factors for ischemic complications with NET for UA in elderly patients
| Univariate analysis | Multivariate analysis | ||
|---|---|---|---|
| Odds ratio (95% CI) | |||
| Patient characteristics | |||
| Age ≥80 | 0.62 | ||
| Sex: Female | 0.38 | ||
| mRS 0–2 before treatment | 0.01 | 0.56 (0.34–0.94) | 0.03 |
| Characteristics of AN | |||
| Symptomatic | 0.04 | 1.34 (0.87–2.05) | 0.18 |
| ≥10 mm | 0.33 | ||
| Site of AN | |||
| ICA | 1 | ||
| ACA | 0.57 | ||
| MCA | 0.06 | 0.33 (0.12–0.92) | 0.04 |
| Posterior circulation | 0.03 | 1.23 (0.80–1.90) | 0.34 |
| Procedure | |||
| General anesthesia | 0.43 | ||
| Balloon-assisted | <0.01 | 0.65 (0.41–1.04) | 0.07 |
| Stent-assisted | <0.01 | 1.43 (0.93–2.20) | 0.11 |
| Proximal balloon protection | 0.52 | ||
| Complete obliteration | 0.03 | 0.66 (0.44–0.97) | 0.03 |
| Preoperative antiplatelet therapy | |||
| DAPT | 0.39 | ||
| Aspirin | 0.80 | ||
| Clopidogrel | 0.64 | ||
| Cilostazol | 0.62 | ||
Statistically significant. ACA: anterior cerebral artery, AN: aneurysm, DAPT: dual antiplatelet therapy, ICA: internal carotid artery, MCA: middle cerebral artery, mRS: modified Rankin Scale, NET: neuroendovascular therapy, UA: unruptured aneurysm.
Risk factors for ischemic complications with CAS in elderly patients
| Univariate analysis | Multivariate analysis | ||
|---|---|---|---|
| Odds ratio (95% CI) | |||
| Patient characteristics | |||
| Age ≥80 | 0.16 | 1.18 (0.82–1.70) | 0.37 |
| Female | 0.67 | ||
| mRS 0–2 before treatment | 0.09 | 0.55 (0.36–0.86) | <0.01 |
| Plaque characteristics | |||
| Symptomatic lesion | 0.33 | ||
| Echolucent | 0.16 | 1.26 (0.83–1.90) | 0.28 |
| TOF high | 0.15 | 1.55 (1.03–2.32) | 0.04 |
| Procedure | |||
| General anesthesia | 0.41 | ||
| Filter protection | 0.06 | 1.31 (0.91–1.89) | 0.15 |
| Distal balloon protection | 0.30 | ||
| Proximal balloon protection | 0.52 | ||
| Open-cell stent | <0.01 | 2.20 (1.50–3.22) | <0.01 |
| Residual stenosis ≥50% | 0.03 | 1.45 (0.33–6.30) | 0.62 |
| Preoperative antiplatelet therapy | |||
| DAPT | 1 | ||
| Aspirin | 0.34 | ||
| Clopidogrel | 0.12 | 0.80 (0.53–1.22) | 0.30 |
| Cilostazol | 0.50 | ||
Statistically significant. CAS: carotid artery stenting, DAPT: dual antiplatelet therapy, mRS: modified Rankin Scale, TOF: time-of-flight magnetic resonance angiography.